Opinion|Videos|December 22, 2023
Clinical Perspectives in Later Line Therapies for R/R DLBCL
Author(s)Matthew A. Lunning, DO, FACP
Expert shares clinical perspectives and treatment considerations regarding use of later lines of therapy for patients with R/R diffuse large B-cell lymphoma.
Advertisement
Episodes in this series
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Adding subcutaneous epcoritamab to R-CHOP significantly improves PFS in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
2
Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia
3
FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer
4
c-Met ADC Temab-A Gains 2 FDA Breakthrough Designations in CRC, NSCLC
5